ShareValue scores for MXCT.LSE: Valuation 54, Quality 52, Growth 37, Health 44.

MaxCyte Inc logo

MXCT.LSE
LSE

MaxCyte Inc

£0.01(+63.83%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

6% to 16%
Valuation
54
Fair Value
Price vs Value
Quality
52
Moderate
Business Strength
Growth
37
Weak
Revenue & Earnings
Health
44
Moderate
Financial Stability
Momentum
14
Bearish
Price Trend

Company Details

About

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland. Address: 9713 Key West Avenue, Rockville, MD, United States, 20850

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026